First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)
Sponsor: Brenus Pharma
Listed as NCT06934538, this PHASE1/PHASE2 trial focuses on Unresectable Locally Advanced Colorectal Cancer and Unresectable Metastatic Colorectal Cancer and remains actively recruiting participants. Sponsored by Brenus Pharma, it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
3 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brenus Pharma
For direct contact, visit the study record on ClinicalTrials.gov .